Efficacy and safety of anlotinib, a multikinase angiogenesis inhibitor, in combination with epirubicin in preclinical models of soft tissue sarcoma

BACKGROUND: Anlotinib is a novel, orally administered, multitarget receptor tyrosine kinase inhibitor. It functions by inhibiting tumor angiogenesis and proliferative signaling pathways. In this study, we aimed to investigate the efficacy and safety of anlotinib plus epirubicin in a sarcoma patient‐...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Zhi‐Ming, Zhang, Shi‐Long, Yang, Hua, Zhuang, Rong‐Yuan, Guo, Xi, Tong, Han‐Xing, Zhang, Yong, Lu, Wei‐Qi, Zhou, Yu‐Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7221313/
https://www.ncbi.nlm.nih.gov/pubmed/32181596
http://dx.doi.org/10.1002/cam4.2941

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7221313/
https://www.ncbi.nlm.nih.gov/pubmed/32181596
http://dx.doi.org/10.1002/cam4.2941

Ejemplares similares